Synthetic peptides and random copolymers for the treatment of autoimmune disorders
AssigneeNational Institute of Immunology
InventorsAvadhesha Surolia, Ravi Kant Gautam, Vishnu Kumar Dwivedi, Sarika Gupta
Life of this patent
Estimating the term…
Abstract
Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or β3-homo amino acid.
Claims27
A synthetic peptide for amelioration of a demyelinating disorder comprising at least 5 amino acids with valine at position PI, tyrosine at position P4 and lysine at position P5, wherein the peptide consists of at least one β-amino acid and/or β3-homo amino acid.
A synthetic random copolymer of
- a. tyrosine, glutamic acid, alanine and lysine, or
- b. tyrosine, phenylalanine, alanine and lysine, or
- c. tryptophan;
- valine, alanine and lysine
- wherein alanine is β-alanine (Ap) and/or β-homoalanine (Ap3);
- lysine is (β-lysine (Kp) and/or β-homolysine (Kp3), tyrosine is β-tyrosine (Yp) and/or β-homotyrosine (Yp3);
- valine is β-valine (Vp) and/or β-homovaline (Vp3);
- glutamic acid is β-glutamic acid (Ep) and/or β-homoglutamic acid (Ep3);
- phenylalanine is β-phenylalanine (Fp) and/or β-homophenylalanine (Fp3) and tryptophan is β-tryptophan (Wp) and/or β-homotryptophan (Wp).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.